Company Announcement Office
Australian Stock Exchange Limited
Dear Sir/Madam
Re: TGA approves Pharmasafe’s Liver Bioguard as listed product
Pharmasafe enters into Distribution Agreement with GoConnect for Liver
Bioguard
Sino Securities International Ltd (“SSI”) and Pharmasafe Pty Ltd (“Pharmasafe”) are pleased to
advise that Pharmasafe’s Chinese herbal remedy, Liver Bioguard, has received final approval
from the Australian Therapeutic Goods Administration for sale as a listed product. Professor
TC Lin and SSI joined forces in January 2002 to establish Pharmasafe to promote and
distribute complementary Chinese medicine. Liver Bioguard is the first complementary
Chinese medicine product owned and to be distributed by Pharmasafe. SSI holds 40% of
Pharmasafe.
GoConnect Ltd (“GCN”) is also pleased to advise that its wholly owned subsidiary, GoConnect
Australia Pty Ltd (“GAP”) has entered into an agreement with Pharmasafe Pty Ltd
(“Pharmasafe”) for GAP to develop the Pharmasafe Internet site located at
www.pharmasafe.com.au and to act as exclusive Internet distribution agent for Pharmasafe
products in return for a revenue share on sales. The first product that will be distributed via the
Pharmasafe website will be Liver Bioguard, a Chinese herbal remedy developed by Professor
Lin from over 20 years of research and practical application. Liver Bioguard helps to restore
the human liver, affected by viral infections, to normal conditions.
The liver is the largest gland in the body. The liver filters blood from both the portal and
systemic circulations. The body depends on the liver to regulate, synthesize, store, and secrete
many important proteins and nutrients and to purify, transform, and clear toxic or unneeded
substances. Normal liver functions can be affected by a number of diseases. Most commonly,
the liver can be impaired by Hepatitis related to viral infections or medications and cirrhosis
related to alcoholism. Hepatitis B Virus (“HBV”) Infection is the most common form of viral
infection of the liver: HBV is 100 times more infectious than HIV, the virus that can cause
AIDS. An estimated 350 million people are infected globally with HBV. Approximately 1
million die each year from complications from HBV. The next most common form of liver
viral infection is Hepatitis C Virus (“HCV”) Infection which cannot be vaccinated against. 3%
of the world's population is infected with HCV, or approximately 170 million.
GoConnect Limited
ACN 089 240 353
Level 6, 43-51 Queen Street
Melbourne Victoria 3000
Australia
Tel 61 3 9993 7000
Fax 61 3 9993 7099
Pharmasafe’s Liver Bioguard works to restore the viral infected liver to normal functions by
restoring the body’s natural immunity to a state that enables the body to combat liver viral
infections and improves well-being to the body. Liver Bioguard can be ordered directly from
www.pharmasafe.com.au.
------------
greetz
Jovi